Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 2/20 | 0.33 |
| ▸ | RXRG | P48443 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17484415 | 0.88 | CA2 (0.46) | CES1RXRARXRBRXRGCA2 | |
| SCHEMBL13573443 | 0.79 | PDK2 (0.37) | CA2 | |
| SCHEMBL17625655 | 0.79 | YWHAG (0.44) | CA2TDP1L3MBTL1 | |
| SCHEMBL17625658 | 0.77 | KMT2A (0.49) | L3MBTL1 | |
| SCHEMBL24623569 | 0.76 | KMT2A (0.49) | HDAC1HDAC8 | |
| SCHEMBL16385087 | 0.76 | KMT2A (0.34) | — | |
| SCHEMBL20763906 | 0.76 | PDK2 (0.36) | CA2TDP1L3MBTL1 | |
| SCHEMBL24209554 | 0.76 | LOXL2 (0.41) | CA2 | |
| SCHEMBL17600535 | 0.75 | KIF11 (0.49) | CES1RXRARXRBRXRGORAI1 | |
| SCHEMBL17625649 | 0.74 | KMT2A (0.54) | CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10693072-B2 | Diazirine containing organic electronic compositions and device thereof | PROMERUS, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10303060-B2 | Diazirine compounds and compositions derived therefrom | PROMERUS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190157558-A1 | DIAZIRINE CONTAINING ORGANIC ELECTRONIC COMPOSITIONS AND DEVICE THEREOF | PROMERUS, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10256409-B2 | Diazirine containing organic electronic compositions and device thereof | PROMERUS, LLC (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180186747-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | PROMERUS, LLC (US) | 2018-07-05 | — | — | US | disclosed |
| US-9938241-B2 | Diazirine compounds and compositions derived therefrom | PROMERUS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170279048-A1 | DIAZIRINE CONTAINING ORGANIC ELECTRONIC COMPOSITIONS AND DEVICE THEREOF | PROMERUS, LLC (US) | 2017-09-28 | — | — | US | disclosed |
| US-20160083352-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083352-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | RDX, AOX1, ALDH1A2 | CES1 1674/4885RXRA 30/4885RXRB 71/4885 |
| US-20180186747-A1 | DIAZIRINE COMPOUNDS AND COMPOSITIONS DERIVED THEREFROM | ZYX, AOX1, RDX | CES1 3783/4885RXRA 192/4885RXRB 316/4885 |
| US-10303060-B2 | Diazirine compounds and compositions derived therefrom | ZYX, AOX1, RDX | CES1 3783/4885RXRA 192/4885RXRB 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.